Can You Become Immune to Semaglutide Over Time?

Step 1: Understanding what 'becoming immune' actually means here

One of the most common worries people share with prescribers is the feeling that Wegovy has stopped working. It is easy to reach for the word "immunity", but true immunological resistance (where the body manufactures antibodies to block a drug) is not what the research shows happening with semaglutide. Studies from the STEP programme, published in the New England Journal of Medicine, tracked participants for 68 weeks and found that weight loss continued at the 2.4mg maintenance dose throughout most of the treatment period, eventually levelling off as expected.

What the body does do is adapt. As weight falls, resting metabolic rate decreases, appetite-regulating hormones shift, and the biological "pull" back toward a higher body weight increases. This is normal human physiology, not a failure of the medicine and not an allergy to it. Calling it immunity does a subtle disservice, it makes the plateau feel permanent when it often is not.

That said, the adaptation is real and it matters clinically. Recognising it as the actual mechanism is the first step toward doing something useful about it. Our page on whether Wegovy becomes less effective over time goes into the plateau evidence in more detail.

Step 2: Recognising the signs that your response is genuinely changing

There is a difference between a temporary slow patch and a sustained plateau. Most people experience a natural deceleration in weight loss after the first few months even when treatment is working well, the early weeks often produce faster results because the dose is still escalating and the calorie deficit is larger relative to body weight. A true plateau, by contrast, tends to persist for eight weeks or more despite consistent adherence to the injection schedule, diet and activity guidance.

The NHS medicines page for semaglutide notes that the medicine works alongside a reduced-calorie diet and increased activity, and that both remain important throughout treatment. A plateau that coincides with returning to earlier eating habits is a different clinical picture from one that arrives without any lifestyle change. Your prescriber will want to understand which it is.

Some people also wonder whether taking semaglutide alongside other medicines might be affecting their response. If you are curious about how other medications interact with semaglutide, that is a conversation worth raising directly at your next clinical review.

Keeping a simple weekly record of weight and any symptoms is genuinely useful when that conversation happens.

Step 3: What prescribers can do when semaglutide seems to stop pulling its weight

A prescriber has several clinical pathways available when a plateau is confirmed. The first is dose review: if a patient is still on a sub-maintenance dose, moving to the 2.4mg weekly maintenance dose (or, where clinically appropriate, the 7.2mg dose approved by the MHRA in early 2026) may restart progress. For guidance on how to access Wegovy through a regulated UK pharmacy, the process always begins with a clinical assessment rather than a product selection.

Where the maximum tolerated semaglutide dose has been reached and weight loss has genuinely stalled, a switch to a different mechanism may be considered. Tirzepatide acts on two gut-hormone receptors rather than one, and the SURMOUNT-5 head-to-head trial (published 2025) found it produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. Whether that switch is appropriate depends on individual health history, contraindications and clinical judgement. You can explore the treatment options available through nume as background reading before speaking to a prescriber.

NICE's recommendation for semaglutide (TA875) notes that continuing treatment should be reviewed if less than 5% weight loss is achieved after six months on the maintenance dose. That is a useful benchmark, not a cliff edge, it is a prompt for clinical review, not automatic discontinuation.

Step 4: What the evidence does not yet show, and why that matters

Research into long-term semaglutide use beyond two years is still accumulating. What we know from the STEP 1 withdrawal study is instructive: when semaglutide was stopped, most participants regained a significant portion of the weight they had lost within 12 months. This tells us the medicine is doing active, ongoing work, which argues against true tolerance developing in the way people fear.

For a broader look at how semaglutide interacts with the body's systems over time, the relationship between semaglutide and the immune system is a separate and interesting question in its own right, touching on emerging research into inflammation and GLP-1 receptors beyond the gut. It is early-stage science, but worth knowing exists.

If you have specific concerns about how your immune system might be responding to treatment, our page on whether Wegovy affects the immune system covers what is currently established and what remains uncertain. These are not questions to set aside, raising them with a clinician is exactly the right move. Speak to our prescribers through a free consultation if you would like a personalised clinical view on how your treatment is going.